Tetherin antagonism by primate lentiviral Nef proteins

Current HIV Research

Volumn 9, Issue 7, 2011, Pages 514-523

  Sauter, Daniel ^a   Kirchhoff, Frank ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Host restriction factor; Intrinsic immunity; Nef; Primate lentiviral evolution; Species barrier; Species specificity; Tetherin; Zoonosis

Indexed keywords

MEMBRANE PROTEIN; NEF PROTEIN; TETHERIN PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CERCOCEBUS; CHIMPANZEE; EBOLA VIRUS; GORILLA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INFLUENZA VIRUS; LENTIVIRINAE; MOLECULAR EVOLUTION; MOLECULAR MECHANICS; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIGENS, CD; BIOLOGICAL EVOLUTION; GENE PRODUCTS, NEF; GPI-LINKED PROTEINS; HIV; HIV-1; HIV-2; HUMANS; LENTIVIRUS INFECTIONS; LENTIVIRUSES, PRIMATE; PRIMATES; SPECIES SPECIFICITY; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS RELEASE;

EID: 84856423239     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211798842044     Document Type: Article

References (111)

1. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350: 508-11.
2. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2: 338-42.
3. Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC. Optimal infectivity in vitro of HIV-1 requires an intact nef gene. J Virol 1994; 68: 2906-14.
4. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB. The HIV-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994; 179: 101-14.
5. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD. The importance of nef in the induction of HIV-1 replication from primary quiescent CD4 lymphocytes. J Exp Med 1994; 179: 115-23.
6. Aiken C, Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995; 69: 5048-56.
7. Schwartz O, Marechal V, Danos O, Heard JM. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 1995; 69: 4053-59.
8. Luciw, PA, Cheng-Mayer C, Levy JA. Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication. Proc Natl Acad Sci USA 1987; 84: 1434-38.
9. Niederman TM, Thielan BJ, Ratner L. Human immunodeficiency virus type 1 negative factor is a transcriptional silencer. Proc Natl Acad Sci USA 1989; 86: 1128-32.
10. Kirchhoff F, Schindler M, Specht A, Arhel N, Munch J. Role of Nef in primate lentiviral immunopathogenesis. Cell Mol Life Sci 2008; 65: 2621-36.
11. Foster JL, Garcia JV. Role of Nef in HIV-1 replication and pathogenesis. Adv Pharmacol 2007; 55: 389-409.
12. Roeth JF, Collins KL. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev 2006; 70: 548-63.
13. Ariën KK, Verhasselt B. HIV Nef: role in pathogenesis and viral fitness. Curr HIV Res 2008; 6: 200-8.
14. Renkema GH, Saksela K. Interactions of HIV-1 NEF with cellular signal transducing proteins. Front Biosci 2000; 5: 268-83.
15. Fackler OT, Alcover A, Schwartz O. Modulation of the immunological synapse: a key to HIV-1 pathogenesis? Nat Rev Immunol 2007; 7: 310-17.
16. Kestler HW, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991; 65: 651-62.
17. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuatted quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-91.
18. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Absence of intact nef sequences in a long-term, nonprogressing survivor of HIV-1 infection. N Engl J Med 1995; 332: 228-32.
19. Arhel NJ, Kirchhoff F. Implications of Nef: host cell interactions in viral persistence and progression to AIDS. Curr Top Microbiol Immunol 2009; 33: 147-75.
20. Geyer M, Fackler OT, Peterlin BM. Structure-function relationships in HIV-1 Nef. EMBO Rep 2001; 2: 580-5.
21. Schindler M, Munch J, Kutsch O, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006; 125: 1055-67.
22. Münch J, Rajan D, Schindler M, et al. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol 2007; 81: 13852-64.
23. Arhel N, Lehmann M, Clauss K, Nienhaus GU, Piguet V, Kirchhoff F. The inability to disrupt the immunological synapse between infected human T cells and APCs distinguishes HIV-1 from most other primate lentiviruses. J Clin Invest. 2009; 119: 2965-75.
24. Munch J, Schindler M, Wildum S, et al. Primary sooty mangabey simian immunodeficiency virus and human immunodeficiency virus type 2 nef alleles modulate cell surface expression of various human receptors and enhance viral infectivity and replication. J Virol 2005; 79: 10547-60.
25. Hrecka K, Swigut T, Schindler M, Kirchhoff F, Skowronski J. Nef proteins from diverse groups of primate lentiviruses downmodulate CXCR4 to inhibit migration to SDF-1 chemokine. J Virol 2005; 79: 10650-59.
26. Swigut T, Shody N, Skowronski J. Mechanism for down-regulation of CD28 by Nef. EMBO J 2001; 20: 1593-604.
27. Bell I, Schaefer TM, Trible RP, Amedee A. Reinhart TA. Downmodulation of the costimulatory molecule, CD28, is a conserved activity of multiple SIV Nefs and is dependent on histidine 196 of Nef. Virology 2001; 283: 148-58.
28. Jia B, Serra-Moreno R, Neidermyer W, et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLOS Pathog 2009; 5: 1000429.
29. Sauter D, Schindler M, Specht A, et al. Tetherin-driven evolution of Vpu and Nef function and the emergence of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009; 6: 409-21.
30. Zhang F, Wilson SJ, Landford WC, et al. Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin Antagonists. Cell Host Microbe 2009; 6: 54-67.
31. Kupzig S, Korolchuk V, Rollason R, et al. Bst-2/HM1.24 is a raftassociated apical membrane protein with an unusual topology. Traffic 2003; 4: 694-709.
32. Andrew AJ, Kao S, Strebel K. The C-terminal hydrophobic region in human BST-2/tetherin functions as a second transmembrane motif. J Biol Chem 2011; [Epub ahead of print].
33. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994; 84: 1922-30.
34. Ishikawa J, Kaisho T, Tomizawa H, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995; 26: 527-34.
35. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-30.
36. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3: 245-52.
37. Bartee E, McCormack A, Fruh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLOS Pathog 2006; 2: 107.
38. Perez-Caballero D, Zang T, Ebrahimi A, et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009; 139: 499-511.
39. Douglas JL, Gustin JK, Viswanathan K, et al. The great escape: viral strategies to counter BST-2/tetherin. PLOS Pathog 2010; 6: 1000913.
40. Dubé M, Bego MG, Paquay C, Cohen ÉA. Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 2010; 7: 114.
41. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 2010; 9: 388-96.
42. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010; 8: 55-67.
43. Malim MH, Emerman M. HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe 2008; 3: 388-98.
44. Neil S, Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009; 29: 569-80.
45. Sauter D, Specht A, Kirchhoff F. Tetherin: holding on and letting go. Cell 2010; 141: 392-8.
46. Hinz A, Miguet N, Natrajan G, et al. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 2010; 7: 314-23.
47. Andrew AJ, Miyagi E, Kao S, Strebel K. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009; 8: 80.
48. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. Inhibition of Lassa and Marburg Virus Production by Tetherin. J Virol 2009; 83: 2382-85.
49. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 2007; 120: 3850-58.
50. Dietrich I, McMonagle EL, Petit SJ, et al. Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J Virol 2011; 85: 5840-52.
51. Gottlinger HG, Dorfman T, Cohen EA, Haseltine WA. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sc USA 1993; 90: 7381-5.
52. Jouvenet N, Neil SJ, Zhadina M, et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009; 83, 1837-44.
53. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sc USA 2009; 106: 2886-91.
54. Mansouri M, Viswanathan K, Douglas JL, et al. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 2009; 83: 9672-81.
55. Radoshitzky SR, Dong L, Chi X et al. Infectious Lassa virus but not filoviruses is restricted by BST-2/tetherin. J Virol 2010, 84: 10569-80.
56. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. Inhibition of Lassa and Marburg Virus Production by Tetherin. J Virol 2009; 83: 2382-85.
57. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. Interfero-induced cell membrane proteins, IITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 2010; 84(24): 12646-57.
58. Xu F, Tan J, Liu R, et al. Tetherin inhibits prototypic foamy virus release. Virol J 2011; 8: 198.
59. Yang SJ, Lopez LA, Hauser H, et al. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 2010; 7: 13.
60. Le Tortorec A, Neil SJ 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 2009; 83, 11966-78.
61. Gupta RK, Mlcochova P, Pelchen-Matthews A, et al. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci USA 2009; 106: 20889-94.
62. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009, 106: 2886-91.
63. Lopez LA, Yang SJ, Hauser H, et al. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 2010; 84: 7243-55.
64. Pardieu C, Vigan R, Wilson SJ, et al. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLOS Pathog 2010; 6: 1000843.
65. Schmökel J, Sauter D, Schindler M, et al. The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses. J Virol 2011; 85: 742-52.
66. Strebel K, Klimkait T, Maldarelli F, Martin MA. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 1989; 63: 3784-91.
67. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci USA 2003; 100: 15154-9.
68. Ross TM, Oran AE, Cullen BR. Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Curr Biol 1999; 9: 613-21.
69. Paiardini M, Pandrea I, Apetrei C, Silvestri G. Lessons learned from the natural hosts of HIV-related viruses. Annu Rev Med 2009; 60: 485-95.
70. Sodora DL, Allan JS, Apetrei C, et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 2009; 15: 861-5.
71. Lim ES, Emerman M. Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST-2. J Virol 2009; 83: 11673-81.
72. Erikson E, Adam T, Schmidt S, et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci U S A 2011; 108: 13688-93.
73. Homann S, Smith D, Little S, Richman D, Guatelli J. Upregulation of BST-2/tetherin by HIV infection in vivo. J Virol 2011 [Epub ahead of print]
74. Miyagi E, Andrew AJ, Kao S, Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A 2009; 106: 2868-73.
75. Varthakavi V, Smith R, Martin K, et al. 2006 The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 2006; 7: 298-307.
76. Dubé M, Roy BB, Guiot-Guillain P, et al. Suppression of Tetherinrestricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 2009; 83: 4574-90.
77. Douglas JL, Viswanathan K, Mccarroll MN, et al. Vpu Directs the Degradation of the Human Immunodeficiency Virus Restriction Factor BST-2/Tetherin via a TrCP-Dependent Mechanism. J Virol 2009; 83: 7931-47.
78. Goffinet C, Allespach I, Homann S, et al. HIV-1 Antagonism of CD317 Is Species Specific and Involves Vpu-Mediated Proteasomal Degradation of the Restriction Factor. Cell Host and Microbe 2009; 5: 285-97.
79. Iwabu Y, Fujita H, Kinomoto M, et al. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 2009; 1-22.
80. Mangeat B, Gers-Huber G, Lehmann M, et al. HIV-1 Vpu Neutralizes the Antiviral Factor Tetherin/BST-2 by Binding It and Directing Its Beta-TrCP2-Dependent Degradation. PLoS Pathog 2009; 5: e1000574.
81. Mitchell R, Katsura C, Skasko M, et al. Vpu Antagonizes BST-2-Mediated Restriction of HIV-1 Release via β-TrCP and Endo-Lysosomal Trafficking. PLoS Pathog 2009; 5: e1000450.
82. Chaudhuri R, Lindwasser OW, Smith WJ, Hurley JH, Bonifacino JS. Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor. J Virol 2007; 81: 3877-90.
83. Lindwasser OW, Smith WJ, Chaudhuri R, et al. A diacidic motif in human immunodeficiency virus type 1 Nef is a novel determinant of binding to AP-2. J Virol 2008; 82: 1166-74.
84. Zhang F, Landford WN, Ng M, McNatt MW, Bieniasz PD, Hatziioannou T. SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathog. 2011: e1002039.
85. Schwartz S, Felber BK, Fenyö EM, Pavlakis GN. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol 1990; 64: 5448-56.
86. Aghokeng, A. F, Liu, W, Bibollet-Ruche, F, et al. Widely varying SIV prevalence rates in naturally infected primate species from Cameroon. Virology 2006; 345: 174-89.
87. Aghokeng, A. F, Ayouba, A, Mpoudi-Ngole, E, et al. Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new crossspecies transmissions. Infect Genet Evol 2010; 10: 386-96.
88. Fultz PN, Gordon TP, Anderson DC, McClure HM. Prevalence of natural infection with simian immunodeficiency virus and simian T-cell leukemia virus type I in a breeding colony of sooty mangabey monkeys. AIDS 1990; 4: 619-25.
89. Santiago, M. L, Lukasik, M, Kamenya, S, et al. Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees Pan troglodytes schweinfurthii. J Virol 2003; 77: 7545-62.
90. Keele, BF, Jones JH, Terio KA, et al. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 2009; 460: 515-9.
91. Bailes E, Gao F, Bibollet-Ruche F, et al. Hybrid origin of SIV in chimpanzees. Science 2003; 300: 1713.
92. McNatt MW, Zang T, Hatziioannou T, et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009; 5: e1000300.
93. Bozek K, Lengauer T. Positive selection of HIV host factors and the evolution of lentivirus genes. BMC Evol Biol 2010; 10: 186.
94. Gupta RK, Hué S, Schaller T, Verschoor E, Pillay D, Towers GJ. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 2009; 5: 1000443.
95. Kratovac Z, Virgen CA, Bibollet-Ruche F, Hahn BH, Bieniasz PD, Hatziioannou T. Primate lentivirus capsid sensitivity to TRIM5 proteins. J Virol 2008; 82: 6772-77.
96. Gaddis NC, Sheehy AM, Ahmad KM, et al. Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol 2004; 78: 12041-6.
97. Sauter D, Vogl M, Kirchhoff F. Ancient origin of a deletion in human BST2/Tetherin that confers protection against viral zoonoses. Hum Mutat 2011: 10.1002/humu.21571.
98. Gifford RJ, Katzourakis A, Tristem M, Pybus OG, Winters M, Shafer RW. A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution. Proc Natl Acad Sci USA 2008; 105: 20362-7.
99. Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658-61.
100. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-7.
101. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010; 467: 214-7.
102. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302(5647): 1056-60.
103. Mauclère P, Loussert-Ajaka I, Damond F, et al. Serological and virological characterization of HIV-1 group O infection in Cameroon. AIDS 1997; 15: 445-53.
104. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. Lack of adaptation to human tetherin in HIV-1 Group O and P. Retrovirology. 2011; 8: 78.
105. Casartelli N, Sourisseau M, Feldmann J, et al. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 2010, 6: e1000955.
106. Jolly C, Booth NJ, Neil SJ. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 2010; 84: 12185-99.
107. Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 2010; 7: 115.
108. Pertel T, Hausmann S, Morger D, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011; 472: 361-5.
109. Lepelley A, Louis S, Sourisseau M, et al. Innate sensing of HIVinfected cells. PLoS Pathog 2011; e1001284
110. Dereeper A, Guignon V, Blanc G, et al. Phylogeny. fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res 2008; 36(Web Server issue): W465-9.
111. Watanabe R, Leser GP, Lamb RA. Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology 2011; 417(1): 50-6.